New scan could spot returning prostate cancer at Ultra-Low PSA levels
NCT ID NCT06862856
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study is testing whether a special PET scan using flotufolastat F 18 can detect prostate cancer that has come back after surgery, even when PSA levels are very low (0.20 ng/mL or less). Researchers will scan 50 men with a history of prostate cancer and a rising PSA after prostate removal. The goal is to see how often the scan finds cancer that standard tests might miss.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Flotufolastat F 18 injection (radioactive tracer for PET scan)
What this could lead to
If successful, this could enable earlier and more accurate detection of prostate cancer recurrence, potentially guiding timely treatment decisions.
What could go wrong
This is a small, early-phase study with only 50 participants, so results may not apply to all patients. The scan may also miss some cancers or show false positives.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PROSTATE ADENOCARCINOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Dana Farber Cancer Institute
RECRUITINGBoston, Massachusetts, 02215, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Massachusetts General Hospital
RECRUITINGBoston, Massachusetts, 02114, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••